N-acetylcysteine treatment lowers 4-aminobiphenyl haemoglobin adduct levels in non-smokers.
Rösler
S
S
Walther Straub Institute of Pharmacology and Toxicology, Ludwig-Maximilians-University, Munich, Germany.
Behr
J
J
Richter
E
E
D000328:Adult; D000611:Aminobiphenyl Compounds / Q000097:blood*; D000975:Antioxidants / Q000008:administration & dosage; D018890:Chemoprevention / Q000379:methods; D002849:Chromatography, Gas; D003553:Cystine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D018736:DNA Adducts / Q000032:analysis*; D006454:Hemoglobins / Q000032:analysis*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011446:Prospective Studies; D011658:Pulmonary Fibrosis / Q000097:blood* / Q000188:drug therapy*; D012044:Regression Analysis; D012907:Smoking / Q000097:blood
D000611:Aminobiphenyl Compounds; D000975:Antioxidants; D018736:DNA Adducts; D006454:Hemoglobins; C006757:4-biphenylamine; D003553:Cystine; C030905:N-monoacetylcystine